OCREVUS® (Ocrelizumab) is an immunosuppressive drug used in the treatment of Relapsing and Primary Progressive Multiple Sclerosis.

OCREVUS® is manufactured by Genentech.

Administration and Dosage:

Administration of OCREVUS® is a biweekly intravenous infusion for 2 doses followed by a 6 month maintenance dose.

Common Side Effects:

The more common side effects of OCREVUS® include infusion reactions and infections.

More Information:

Please read the full Prescribing Information for OCREVUS® and discuss any questions you have with your doctor.

Ready to Schedule an Appointment?

Please CLICK HERE to get started.


OCREVUS® is indicated to treat:

  • Multiple Sclerosis